Finanzen von CNS Pharmaceuticals Inc (CNSP)CNSPCNS Pharmaceuticals Inc

Evaluating the bottom line, CNS Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -106.62%, provide a clear picture of how effectively CNSP converts its operational activities into shareholder value.

In the context of the broader market, CNSP competes directly with industry leaders such as BGMS and ACXP. With a market capitalization of $5.75M, it holds a significant position in the sector. When comparing efficiency, CNSP's gross margin of N/A stands against BGMS's 23.51% and ACXP's N/A. Such benchmarking helps identify whether CNS Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

CNS Pharmaceuticals has shown troubling financial performance, with a total revenue of only $3,140 in Q1 2025 and a net income loss of $4,937,046 in Q1 2026. The company has consistently reported negative earnings per share, with the latest EPS at -0.38. The current ratio has dropped to 0.89, indicating potential liquidity issues.